Klin Farmakol Farm. 2021;35(4):112-117 | DOI: 10.36290/far.2021.026

A case of difficult to treat psoriatic arthrtitis

David Suchý

Oddělení klinické farmakologie Fakultní nemocnice v Plzni

Psoriatic arthritis (PsA) is a chronic autoimmune inflammatory disease manifested by involvement of the musculoskeletal system and skin. PsA is considered part of the spondyloarthritis group, which is present in 20-30%of individuals with psoriasis. The introduction of biological therapy has brought substantial improvement in the prognosis of patients not responding to conventional treatment. The success of affecting the tumour necrosis factor α with therapeutic monoclonal antibodies has been followed by extensive research into other potentially suitable molecules. Secukinumab has become the first monoclonal antibody against interleukin-17A introduced into the clinical practice in PsA treatment that is capable of having an effect on the involvement of the musculoskeletal system as well as skin manifestations. This report describes the case of a 50 years old patient with difficult to treat psoriatic arthritis We present this case to show the clinical course of disease and current management strategies of the disease , based on Czech society of rheumatology and European league against rheumatism (EULAR) treatment recommendations.

Keywords: psoriatic arthritis, case report, treatment recommendations, secukinumab.

Published: January 4, 2022  Show citation